Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Boston Medical Group vs Somira Health

Boston Medical Group
Graded #279

Lower grade

vs+0.6000000000000014
Somira Health
Graded #269

Higher grade

The verdict

Somira Health takes it — 62.5/100 to 61.9/100, but only just.

Somira Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Somira Health is a self-pay telehealth platform that connects you with independent licensed providers and compounding pharmacies for GLP-1 weight loss. Boston Medical Group is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBoston Medical Group +2
54
52
Dose & formulationSomira Health +12
52
64
Clinical oversightBoston Medical Group +12
89
77
Labs & monitoringSomira Health +9
53
62
FulfillmentSomira Health +18
65
83
Contract termsBoston Medical Group +30
55
25
Boston Medical Group · left barSomira Health · right bar

The numbers

MetricBoston Medical GroupSomira Health
WeighScore61.9/10062.5/100
GradeCC
Scorecard rank#279#269
Semaglutide$199/mo (starting strength, rising with dose, compounded)$190/mo (compounded)
TirzepatideNot disclosed$285/mo (compounded)
Coverage7 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Boston Medical Group

Graded #279 · C

Strengths

  • An established medical group with a defined 12-week programme rather than an open-ended subscription
  • The price range and the 12-week total are both published, once you reach the costs page
  • Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight

Where it loses points

  • The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
  • The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
  • The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
  • Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
Somira Health

Graded #269 · C

Strengths

  • Transparent flat monthly pricing that does not increase as you titrate (semaglutide $189.99/mo, tirzepatide $284.99/mo)
  • Quarterly plans lower the effective monthly cost (semaglutide $136.66/mo, tirzepatide $221.66/mo)
  • Free overnight shipping, with syringes and alcohol wipes included in every order
  • Simple, fast online intake reviewed by a licensed provider; no insurance required
  • Both weekly compounded GLP-1 options offered: semaglutide and tirzepatide

Where it loses points

  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • The compounding pharmacy partner is not named
  • State-availability list is not published
  • No LegitScript certification displayed
  • New, thin platform with limited public detail on the provider network, lab monitoring, or ongoing support

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard